BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 29265182)

  • 1. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
    Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
    Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.
    Messmer M; Tsai HL; Varadhan R; Swinnen LJ; Jones RJ; Ambinder RF; Shanbhag SP; Borowitz MJ; Wagner-Johnston N
    Leuk Lymphoma; 2019 May; 60(5):1261-1265. PubMed ID: 30656983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
    Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
    Gleeson M; Hawkes EA; Cunningham D; Chadwick N; Counsell N; Lawrie A; Jack A; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Linch D
    Br J Haematol; 2016 Nov; 175(4):668-672. PubMed ID: 27477167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
    Malenda A; Kołkowska-Leśniak A; Puła B; Długosz-Danecka M; Chełstowska M; Końska A; Giza A; Lech-Marańda E; Jurczak W; Warzocha K
    Eur J Haematol; 2020 Jan; 104(1):59-66. PubMed ID: 31606909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
    Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
    Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
    [No Abstract]   [Full Text] [Related]  

  • 13. Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas.
    Gharwan H; Lai C; Grant C; Dunleavy K; Steinberg SM; Shovlin M; Fojo T; Wilson WH
    Leuk Lymphoma; 2016 Jul; 57(7):1616-24. PubMed ID: 27183887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.
    Goldschmidt N; Kleinstern G; Orevi M; Paltiel O; Ben-Yehuda D; Gural A; Libster D; Lavie D; Gatt ME
    Cancer Chemother Pharmacol; 2016 May; 77(5):1053-60. PubMed ID: 27056383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
    Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
    Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
    Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
    Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
    Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
    Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.